Williams, Peter E

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial

Margolis, D. A., Brinson, C. C., Smith, G. H. R., de Vente, J., Hagins, D. P., Eron, J. J., Griffith, S. K., Clair, M. H. S., Stevens, M. C., Williams, P. E., et al. (2015) · The Lancet Infectious Diseases

HIV/AIDS drug development and treatmentHIV/AIDS Research and Interventions

Cited by 204

Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission

Kovarova, M., Council, O. D., Date, A. A., Long, J. M., Nochii, T., Belshan, M., Shibata, A., Vincent, H., Baker, C. E., Thayer, W. O., et al. (2015) · PLOS Pathogens

HIV/AIDS Research and InterventionsHIV/AIDS drug development and treatment

Cited by 77